Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Estimated cardiac deaths associated with treating chronic lymphocytic leukemia with ibrutinib versus zanubrutinib in the United States

View Full Paper
Ask AI
Bookmark
Share

Authors

SCSwetha ChallagullaQFQianhong FuRWRhys Williams

Discussion

Loading...

Member takes

Overview

Modeling analysis estimates zanubrutinib may reduce cardiac deaths in 2L+ CLL, suggesting better outcomes compared to ibrutinib.

Key Points

  • To estimate cardiac deaths associated with ibrutinib versus zanubrutinib in treating chronic lymphocytic leukemia (CLL).
  • Conducted modeling analysis using data from ALPINE, SEQUOIA, and RESONATE-2 trials.
  • Applied number needed to treat (NNT) to estimate avoidable cardiac deaths.
  • Utilized real-world data from the Symphony Integrated Dataverse for CLL patients treated with ibrutinib.
  • Estimated up to 255 cardiac deaths could be avoided in 2L+ CLL by using zanubrutinib instead of ibrutinib.
  • For every 54 patients treated with zanubrutinib in the 2L+ setting, one cardiac death could be prevented over 10 years.
  • In the 1L setting, up to 266 deaths may be avoided with zanubrutinib, preventing one cardiac death for every 46 treated.

Cite This Study

Challagulla et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d3f8https://doi.org/10.1182/blood-2025-7443
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Number of cardiac deaths associated with ibrutinib versus zanubrutinib for the treatment of chronic lymphocytic leukemia: A European risk-based estimation2025
  2. 2Cardiotoxicity and safety of zanubrutinib versus chemoimmunotherapy in chronic lymphocytic leukemia: a real-world retrospective cohort study using the TriNetX registry2026
  3. 3Number of patients needed to treat to prevent one atrial fibrillation event with zanubrutinib versus ibrutinib and acalabrutinib in B-cell malignancies2025
  4. 4Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort2026 · 4 citations
  5. 5Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib2024 · 21 citations